-
Reparixin: A Causal Map for IL-8 Signaling
2026-09-04
Reparixin is a CXCR1/2 inhibitor for dissecting IL-8-driven inflammation, migration, and tumor signaling. This article presents a receptor-centered framework that connects MRSA extracellular-vesicle biology with rigorous assay design and translational interpretation.
-
EMD638683: SGK1 Inhibitor Workflow Guide
2026-09-04
Build a target-engagement workflow around EMD638683 to connect SGK1 signaling with NDRG1 phosphorylation, endothelial mechanics, actin remodeling, and cancer-cell responses. This practical guide separates literature-backed parameters from screening recommendations for cardiovascular and tumor research.
-
Pentoxifylline Workflows for Inflammation Research
2026-09-03
Build reproducible Pentoxifylline assays around cAMP modulation, ICAM-1 measurement, and cytokine profiling. This workflow distinguishes reference-anchored monocyte experiments from exploratory psoriasis, infection, fertility, and sepsis applications.
-
Genotyping: A Translational Control Point in Atherosclerosis
2026-09-03
Mechanistic mouse studies are only as reliable as the genetic assignments behind them. This thought-leadership article connects the Direct Mouse Genotyping Kit Plus with rigorous validation of EP4-deficient atherosclerosis models, showing how rapid, purification-free PCR can strengthen colony decisions, reduce pre-analytical uncertainty, and support more defensible translational conclusions.
-
MK-5108 (VX-689) Aurora A Workflows
2026-09-02
MK-5108 (VX-689) combines exceptional biochemical selectivity for Aurora A with practical utility in cell-cycle, retinoblastoma, and xenograft research. This guide turns the evidence into reproducible assay workflows, dose-design strategies, and troubleshooting checkpoints.
-
Resazurin sodium salt for Metabolic Viability Assays
2026-09-02
Resazurin sodium salt converts cellular redox activity into a fluorescence signal that can scale from L-cell metabolism studies to automated cytotoxicity screens. This guide connects assay design with the gut microbiota–GLP-1 findings of a recent Nature Metabolism study while emphasizing controls, fresh preparation, and the limits of treating metabolic activity as direct viability.
-
Aurora-A Targeting in Translational Oncology
2026-09-01
AURKA overexpression in high-risk retinoblastoma strengthens the case for selective Aurora-A inhibition as a mechanistic research strategy. This article connects the biology of MK-5108 (VX-689) with practical assay design, selectivity interpretation, and translational decision-making.
-
ZK53 and Human ClpP Small-Molecule Design
2026-09-01
The 2025 Future Medicinal Chemistry review organizes recent small-molecule strategies for human mitochondrial ClpP, emphasizing activator design, structure–activity relationships, and anticancer pharmacology. Its discussion of optimized compounds such as ZK53 shows how selective ClpP activation can connect mitochondrial proteostasis disruption with tumor-cell stress, while also highlighting challenges in selectivity, pharmacokinetics, and safety.
-
Cy3-UTP for RNA Trafficking Assay Design
2026-08-31
Cy3-UTP is more than a fluorescent RNA labeling reagent: it can help researchers design better trafficking assays. This guide connects in vitro transcription RNA labeling with interpretation of lipid nanoparticle transport while distinguishing fluorescence, uptake, and functional delivery.
-
Astrocytic GAT-3 Controls Dentate Gyrus Memory
2026-08-31
The reference study identifies astrocytic GAT-3 as an active regulator of entorhinal cortex–dentate gyrus synaptic transmission rather than merely a GABA-clearance mechanism. Its combination of electrophysiology, optogenetics, calcium signaling, and behavioral analysis links GAT-3-dependent astrocyte activation to GluN2B-NMDAR-mediated excitation and contextual fear memory.
-
RapaLink-1: Designing Better mTOR Dormancy Assays
2026-08-30
RapaLink-1 is a third-generation mTOR inhibitor with a bivalent mechanism suited to dissecting durable mTORC1 inhibition, tumor cell suppression, and dormancy-like states. This article translates a recent embryonic dormancy protocol into an assay-design framework while separating established evidence from testable applications.
-
Proteoform-Specific Drug Interactions in Native Membranes
2026-08-29
Lutomski and colleagues developed a native mass-spectrometry workflow that releases membrane proteins and signaling complexes directly from retina rod disc membranes, then sequences their individual proteoforms. The study shows that palmitoylation and other lipid modifications can control membrane association, protein assembly, and off-target ligand interactions, providing a framework for more precise drug-target analysis.
-
Telmisartan in Cardiac Hypertrophy Research
2026-08-28
Use Telmisartan as a defined AT1-receptor perturbation tool in angiotensin II-driven cardiac hypertrophy and hypertension research. Its upstream mechanism complements emerging RIP3/CaMKII studies, enabling cleaner comparisons between receptor blockade, downstream signaling, and cellular remodeling.
-
Elbasvir/Grazoprevir: Evidence for HCV Genotype 1/4 Therapy
2026-08-28
The 2021 review by Wang, Huang, and Yu examines elbasvir/grazoprevir as a dual direct-acting antiviral regimen that combines NS5A and NS3/4A inhibition for hepatitis C. Its main practical contribution is the integration of pharmacology, resistance, efficacy, safety, and special-population evidence, particularly for HCV genotype 1 and 4 infections and patients with renal disease.
-
Dihydroethidium (DHE): From Signal to Mechanism
2026-08-27
Dihydroethidium (DHE) is a cell-permeable hydroethidine probe for investigating superoxide-associated redox changes in live cells. This article explains how to move beyond red fluorescence intensity toward mechanistic interpretation, using recent sonodynamic lung-cancer research to define assay strengths, controls, and limitations.